AbbVie announced it will present 23 abstracts s at the 31(st) European Academy of Dermatology and Venereology (EADV) Congress, including a late-breaking oral presentation on long-term efficacy and safety data of SKYRIZI(R) (risankizumab) in psoriatic arthritis and real-world data from MEASURE-AD to assess the multidimensional burden of atopic dermatitis. This research demonstrates AbbVie's commitment to deepening the understanding of immune-mediated skin diseases by investing in studies of difficult-to-treat patient populations, certain disease areas with few existing treatment options as well as real-world patient experience. The hybrid congress will take place from September 7-10, in Milan, as well as virtually.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
163.8 USD | +1.85% | +2.61% | +5.69% |
04-30 | Alvotech to Make Humira Biosimilar Adalimumab-ryvk for Quallent | MT |
04-29 | Health Care Up on Growth Optimism -- Health Care Roundup | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+5.69% | 290B | |
+26.08% | 662B | |
+21.85% | 546B | |
-4.77% | 359B | |
+16.97% | 323B | |
+13.68% | 234B | |
+3.65% | 198B | |
-11.12% | 194B | |
+8.08% | 167B | |
-3.40% | 157B |
- Stock Market
- Equities
- ABBV Stock
- News AbbVie Inc.
- AbbVie Showcases New Analyses and Real-World Data Across Multiple Immune-Mediated Skin Diseases at the European Academy of Dermatology and Venereology 2022 Congress